Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sandoz, the generics and biosimilars business of Novartis, has opened its new biomanufacturing facility called BioInject, at Schaftenau in the Tyrolean Alps in Austria.
Subscribe to our email newsletter
It is the result of over 150 million euro worth of investment with creation of 100 highly skilled jobs. In attendance at the event were Austrian dignitaries from national politics and the regional economy.
BioInject is a state-of-the-art facility that will be used to manufacture pre-filled syringes and devices for both Sandoz’s biosimilars and Novartis Pharma’s novel biologics.
This new facility now means that 18,000 syringes can be filled per hour and 100 packaged per minute. It will play an important role in driving the next wave of biosimilars and novel biologics growth at Sandoz and Novartis Pharmaceuticals – growth that will ultimately help address unmet medical needs and broaden patient access to key biologics products.
Sandoz global head of biopharmaceuticals and oncology injectables Carol Lynch said: "BioInject stands as a testament to both Sandoz’ technological leadership in biologics as well as the company’s commitment to further strengthening its global leadership in biosimilars." BioInject will become a central part of Novartis’ biomanufacturing network which also includes facilities in Slovenia, Singapore and France.
Total investment of 2.2 billion euro in Austria since 1996
More than 2.2 billion euro has been invested in Austria since Novartis was first established in 1996. The group currently has over 4,600 employees at four sites and is therefore an important economic contributor particularly in the provinces of Tyrol, Upper Austria and Vienna.
Sandoz has an unwavering commitment to increasing patient access to high-quality, life-enhancing biosimilars. It is the pioneer and global market leaderi and currently markets three biosimilars in over 60 countries around the world.
Sandoz recently became the first company to introduce a biosimilar in the United States, signaling the shift towards more competition and affordability envisaged by US lawmakers when they enacted Biologics Price Competition and Innovation Act (BPCIA). Sandoz has a leading pipeline with several biosimilars across the various stages of development, including five programs in Phase III clinical trials and filing preparation.
As part of the Novartis Group, Sandoz is uniquely positioned to lead the biosimilars industry based on its experience and capabilities in development and manufacturing.